Boyle M J, Dumble L J
Department of Surgery, University of Texas Medical School at Houston, 77030, USA.
Cell Transplant. 1999 Sep-Oct;8(5):543-8. doi: 10.1177/096368979900800509.
Prostacyclin analogs have previously been shown to have not only cytoprotective but also independent immunosuppressive effects. The effect of one such analog, 15AU81, to enhance the immunosuppressive effects of liver was investigated. We have previously demonstrated that cyclosporine (CsA) in conjunction with rapamycin (RAPA) potentiates class I+, class II- donor-specific hepatocytes to prolong rat cardiac and small bowel allograft survival. Brown Norway (BN; RT1n) hepatocytes alone (5 x 10(7)/kg, administered intrasplenically) failed to prolong the survival of BN heart allografts in Wistar Furth (WFu; RT1u) recipients, beyond that of untreated controls (MST = 7.2 +/- 0.8 days). Survival of BN hearts was increased to 11.4 +/- 1.7 days in WFu recipients treated with BN hepatocytes and 50 microg/kg/day 15AU81 administered by continuous s.c. infusion for 14 days using osmotic pumps (p < 0.05). The further addition of RAPA 0.0075 mg/kg/day and CsA 0.375 mg/kg/day delivered for 14 days by continuous i.v. infusion (CIVI) using osmotic pumps (a combination that alone prolonged BN heart allografts in WFu hosts to 18.4 +/- 1.3 days and in conjunction with BN hepatocytes prolonged survival to 27.2 +/- 1.9 days) prolonged allograft survival to 35.2 +/- 5.2 days. In contrast, the survival of small bowel allografts was not enhanced by 15AU81 administration. Survival of BN small bowel transplants in LEW recipients treated with hepatocytes alone (MST = 11.6 +/- 1.5 days) or hepatocytes plus 15AU81 (MST = 10.0 +/- 1.0 days) was similar to controls (MST = 10.2 +/- 1.9 days). Treatment with hepatocytes and RAPA/CsA increased survival to 21.2 +/- 1.5 days. The further addition of 15AU81 failed to augment this (MST = 17.0 +/- 1.9 days). In vitro WFu lymphocyte proliferative responses from animals pretreated with BN hepatocytes, 15AU81, or both treatments, for 2 weeks prior to harvesting, exhibited a reduction of at least 50%, compared to untreated controls upon allostimulation with irradiated BN or ACI spleen cells. These findings demonstrate that 15AU81 interacts favorably with hepatocytes either alone or in conjunction with RAPA and CsA to enhance their immunosuppressive effects on rat heart allograft survival. The failure to enhance small bowel allograft survival may be explained by the inability at this low dosage of 15AU81 to influence the intense graft versus host reaction elicited by small bowel transplants.
前列环素类似物此前已被证明不仅具有细胞保护作用,还具有独立的免疫抑制作用。研究了一种此类类似物15AU81增强肝脏免疫抑制作用的效果。我们之前已经证明,环孢素(CsA)与雷帕霉素(RAPA)联合使用可增强I类阳性、II类阴性供体特异性肝细胞,从而延长大鼠心脏和小肠同种异体移植的存活时间。单独给予棕色挪威大鼠(BN;RT1n)肝细胞(5×10⁷/kg,经脾内注射),未能延长Wistar Furth(WFu;RT1u)受体中BN心脏同种异体移植的存活时间,其存活时间未超过未治疗对照组(平均存活时间 = 7.2±0.8天)。在接受BN肝细胞和通过渗透泵连续皮下输注14天给予50μg/kg/天 15AU81治疗的WFu受体中,BN心脏的存活时间增加到11.4±1.7天(p<0.05)。进一步添加每天0.0075mg/kg的RAPA和每天0.375mg/kg的CsA,通过渗透泵连续静脉输注(CIVI)14天(该组合单独可将WFu宿主中BN心脏同种异体移植的存活时间延长至18.4±1.3天,与BN肝细胞联合使用可将存活时间延长至27.2±1.9天),可将同种异体移植的存活时间延长至35.2±5.2天。相比之下,给予15AU81并不能提高小肠同种异体移植的存活时间。单独接受肝细胞治疗(平均存活时间 = 11.6±1.5天)或接受肝细胞加15AU81治疗(平均存活时间 = 10.0±1.0天)的LEW受体中BN小肠移植的存活时间与对照组(平均存活时间 = 10.2±1.9天)相似。肝细胞与RAPA/CsA联合治疗可将存活时间提高到21.2±1.5天。进一步添加15AU81并不能增强这一效果(平均存活时间 = 17.0±1.9天)。在收获前2周用BN肝细胞、15AU81或两种治疗方法预处理的动物的体外WFu淋巴细胞增殖反应,与未治疗对照组在用辐照的BN或ACI脾细胞进行异体刺激后相比,至少降低了50%。这些发现表明,15AU81单独或与RAPA和CsA联合使用时,能与肝细胞良好相互作用,增强其对大鼠心脏同种异体移植存活的免疫抑制作用。无法提高小肠同种异体移植存活时间的原因可能是在这个低剂量下,15AU81无法影响小肠移植引发的强烈的移植物抗宿主反应。